Historical Valuation
Sutro Biopharma Inc (STRO) is now in the Fair zone, suggesting that its current forward PS ratio of 2.94 is considered Fairly compared with the five-year average of -2.84. The fair price of Sutro Biopharma Inc (STRO) is between 5.10 to 51.45 according to relative valuation methord.
Relative Value
Fair Zone
5.10-51.45
Current Price：12.23
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sutro Biopharma Inc (STRO) has a current Price-to-Book (P/B) ratio of -1.07. Compared to its 3-year average P/B ratio of 0.96 , the current P/B ratio is approximately -210.87% higher. Relative to its 5-year average P/B ratio of 1.48, the current P/B ratio is about -172.37% higher. Sutro Biopharma Inc (STRO) has a Forward Free Cash Flow (FCF) yield of approximately -241.09%. Compared to its 3-year average FCF yield of -110.90%, the current FCF yield is approximately 117.40% lower. Relative to its 5-year average FCF yield of -72.87% , the current FCF yield is about 230.84% lower.
P/B
Median3y
0.96
Median5y
1.48
FCF Yield
Median3y
-110.90
Median5y
-72.87
Competitors Valuation Multiple
AI Analysis for STRO
The average P/S ratio for STRO competitors is 1.91, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO.O) exhibits a P/S ratio of 2.94, which is 53.38% above the industry average. Given its robust revenue growth of 13.77%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for STRO
1Y
3Y
5Y
Market capitalization of STRO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of STRO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is STRO currently overvalued or undervalued?
Sutro Biopharma Inc (STRO) is now in the Fair zone, suggesting that its current forward PS ratio of 2.94 is considered Fairly compared with the five-year average of -2.84. The fair price of Sutro Biopharma Inc (STRO) is between 5.10 to 51.45 according to relative valuation methord.
What is Sutro Biopharma Inc (STRO) fair value?
STRO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sutro Biopharma Inc (STRO) is between 5.10 to 51.45 according to relative valuation methord.
How does STRO's valuation metrics compare to the industry average?
The average P/S ratio for STRO's competitors is 1.91, providing a benchmark for relative valuation. Sutro Biopharma Inc Corp (STRO) exhibits a P/S ratio of 2.94, which is 53.38% above the industry average. Given its robust revenue growth of 13.77%, this premium appears unsustainable.
What is the current P/B ratio for Sutro Biopharma Inc (STRO) as of Jan 10 2026?
As of Jan 10 2026, Sutro Biopharma Inc (STRO) has a P/B ratio of -1.07. This indicates that the market values STRO at -1.07 times its book value.
What is the current FCF Yield for Sutro Biopharma Inc (STRO) as of Jan 10 2026?
As of Jan 10 2026, Sutro Biopharma Inc (STRO) has a FCF Yield of -241.09%. This means that for every dollar of Sutro Biopharma Inc’s market capitalization, the company generates -241.09 cents in free cash flow.
What is the current Forward P/E ratio for Sutro Biopharma Inc (STRO) as of Jan 10 2026?
As of Jan 10 2026, Sutro Biopharma Inc (STRO) has a Forward P/E ratio of -0.75. This means the market is willing to pay $-0.75 for every dollar of Sutro Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sutro Biopharma Inc (STRO) as of Jan 10 2026?
As of Jan 10 2026, Sutro Biopharma Inc (STRO) has a Forward P/S ratio of 2.94. This means the market is valuing STRO at $2.94 for every dollar of expected revenue over the next 12 months.